|
3.1 Tabac
|
|
|
|
3.2 Prévention - Obésité
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
5. Traitements
|
|
|
|
|
PARG inhibitors: tipping the scales with a new experimental drug [Cancer Research UK]
|
|
|
|
|
|
This
strategy has recently seen several promising drugs, collectively called
PARP inhibitors, now being used to treat some women with ovarian
cancer. But they don’t work for everyone. That’s why Dr Donald Ogilvie,
and his team based at Drug Discovery Unit, at Cancer Research UK’s
Manchester Institute, have turned their focus on a different molecule:
PARG.
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
FDA Approves New Use for Lenalidomide in Multiple Myeloma [NCI]
|
|
|
|
|
|
But
because multiple myeloma is such a serious disease, Dr. Huff noted,
“the risk of dying from myeloma, in most [experts’] opinions, far
exceeds the risk of the second cancers.” However, she added, “that is
certainly a discussion that we have with our patients” when considering
potential risks and benefits of lenalidomide treatment.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
NICE set to reject Janssen’s Darzalex for multiple myeloma [PharmaTimes]
|
|
|
|
|
|
Should
the Institute’s position become final, patients who have failed nearly
all existing treatment options will remain unable to access an
innovative and much needed treatment for this incurable form of blood
cancer on the NHS - whilst it is already reimbursed in several European
countries, the firm stressed.
|
|
|
|
|
|
|
|
5.9 AACR
|
|
|
|
5.9.1 ASTRO
|
|
|
|
|
|
|
|
|
6.10 Politiques
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
|
|
|
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
Google DeepMind's NHS deal under scrutiny [BBC News]
|
|
|
|
|
|
More
than a million patient records were shared with DeepMind to build an
app to alert doctors about patients at risk of acute kidney injury
(AKI). The authors said that it was "inexcusable" patients were not told
how their data would be used. Google's DeepMind said that the report
contained "major errors".
|
|
|
|
|
|
|
6.9 Controverses
|
|
|